Daxor Corporation (DXR)
8.12
-0.21 (-2.52%)
At close: Mar 24, 2025, 3:47 PM
8.15
0.36%
After-hours: Mar 24, 2025, 04:00 PM EDT
-2.52% (1D)
| Bid | 8.15 |
| Market Cap | 39.28M |
| Revenue (ttm) | 154.43K |
| Net Income (ttm) | 1.69M |
| EPS (ttm) | -0.09 |
| PE Ratio (ttm) | -90.23 |
| Forward PE | n/a |
| Analyst | Strong Buy |
| Ask | 8.37 |
| Volume | 12,984 |
| Avg. Volume (20D) | 7,748 |
| Open | 8.33 |
| Previous Close | 8.33 |
| Day's Range | 8.10 - 8.33 |
| 52-Week Range | 6.55 - 10.00 |
| Beta | -0.53 |
About DXR
Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions. The company was formerly known as Idant Corporation...
Industry Medical - Instruments & Supplies
Sector Healthcare
IPO Date Jul 25, 1983
Employees 37
Stock Exchange NASDAQ
Ticker Symbol DXR
Website https://www.daxor.com
Analyst Forecast
According to 1 analyst ratings, the average rating for DXR stock is "Strong Buy." The 12-month stock price forecast is $25, which is an increase of 207.85% from the latest price.
Stock Forecasts
